What the business is, and whether it's a good one at a fair price.
Develops, manufactures and sells pharmaceutical formulations across respiratory, cardiac, anti-diabetes and other chronic therapies. In FY26 the business reported two segments: Pharmaceuticals (₹20,617.25 cr, 94.6% of segment revenue) and New ventures (₹1,175.86 cr, 5.4%). The Pharmaceuticals segment covers India branded prescription drugs (One India crossed ₹12,500 cr for the first time, growing 9% YoY), North America generics ($780 mn in FY26; 186 approved ANDAs with 48 under approval; US #1 in Albuterol MDI with 21% share), and One Africa ($483 mn, growing at 1.4x the South African market). New ventures houses newer businesses such as biosimilars, where 1–2 products are to be added per year for the next 5–6 years through the Kemwell joint venture. R&D spend was ₹1,974 cr (7% of FY26 revenue), funding a complex respiratory and peptide pipeline; a US generic Ventolin launch commenced in Q1 FY27 with 6-month competitive generic therapy exclusivity. The largest FY26 cost lines were materials at 20.7% of revenue, employees at 19.1%, and other opex at 26.1%, with capex at 5.7%.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from CIPLA LTD's filed financials and exchange disclosures
CIPLA LTD is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol CIPLA.
Yes. Over the trailing twelve months CIPLA LTD reported a net profit of ₹3,356 Cr on revenue of ₹28,324 Cr.
Yes. The dividend yield is 1.17% at the current price. It paid out 34% of its profit as dividend in FY26.
Effectively yes. It holds ₹760 Cr more cash than debt. Debt stands at 0.01× equity.
On trailing P/E, CIPLA LTD ranks 91 of 169 in Pharmaceuticals — cheaper than 46% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session CIPLA LTD moves 0.71% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by CIPLA LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
